Cart
0

Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Get 20% Free Customization In This Report
LI_18480
Pages: 226
May 2018 | 3277 Views
 
Author's : Sohail Shaikh & Pallavi Jaiswal
Tables: 72
Charts: 65
 

Cancer Therapeutics Market Overview:

The Global Cancer Therapeutics Market was valued at $81,291 million in 2016 and is estimated to reach at $178,863 million by 2023, registering a CAGR of 11.9% from 2017 to 2023. Cancer therapeutics involves the use and administration of chemotherapy and oncology drugs to treat cancer.

Increase in cancer prevalence, surge in collaboration between pharmaceutical companies, and rise in cancer research are the key factors that augment the growth of the cancer therapeutics market. Furthermore, growth in geriatric population is expected to boost the market.

However, high costs associated with oncology drug development along with adverse effects associated with cancer therapeutics are some of the factors that restrain the market growth. Conversely, the upsurge in demand for personalized medicine and high potential of developing nations is expected to provide new opportunities for the market players in future.

The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get more information on this report : Request Sample Pages

The lung cancer segment dominated the cancer therapeutics market, owing to the surge in prevalence of lung cancer and favorable government regulations towards lung cancer therapeutics.

Get more information on this report : Request Sample Pages

A rise in focus of vendors on the emerging markets, such as Asia-Pacific and LAMEA is expected to boost the market growth. Asia-Pacific is projected to witness significant growth in future, owing to increase in R&D investment and surge in cancer awareness. Furthermore, this region presents remarkable opportunities for the venture capitalists and investors, as the developed markets are comparatively saturated.

The report provides an extensive competitive analysis and profiles of the key market players such as F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma, Inc., Pfizer, Inc., Novartis AG, Merck KGaA, and Eli Lilly and Company. The other players in the value chain (not included in the report) include AstraZeneca plc, Bayer AG, and Takeda Pharmaceutical Company Limited.

Key Benefits

  • This report entails a detailed quantitative analysis of the market trends from 2016 to 2023 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
  • Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
  • An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Cancer Therapeutics Market Key Segments:

By Application

  • Blood Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Breast Cancer
  • Cervical Cancer
  • Others

By Top Selling Drugs

  • Revlimid
  • Avastin
  • Herceptin
  • Rituxan
  • Opdivo
  • Gleevec
  • Velcade
  • Imbruvica
  • Ibrance
  • Zytiga
  • Alimta
  • Xtandi
  • Tarceva
  • Perjeta
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle-East
    • Africa
 

Chapter: 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2: EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective

Chapter: 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Market share analysis, 2016
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics

3.6.1. Drivers

3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions and collaborations

3.6.2. Restraints

3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy

3.6.3. Opportunities

3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economics

Chapter: 4: CANCER THERAPEUTICS MARKET, APPLICATION

4.1. Overview

4.1.1. Market size and forecast

4.2. Blood cancer

4.2.1. Key market trends, growth factors & opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Lung cancer

4.3.1. Key market trends, growth factors & opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Breast cancer

4.4.1. Key market trends, growth factors & opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Colorectal cancer

4.5.1. Key market trends, growth factors & opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Prostate cancer

4.6.1. Key market trends, growth factors & opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Other cancers

4.7.1. Key market trends, growth factors & opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

Chapter: 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS

5.1. Overview

5.1.1. Market size and forecast

5.2. Revlimid

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region

5.3. Avastin

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region

5.4. Herceptin

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region

5.5. Rituxan

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region

5.6. Opdivo

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region

5.7. Gleevec

5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region

5.8. Velcade

5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region

5.9. Imbruvica

5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region

5.10. Ibrance

5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region

5.11. Zytiga

5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region

5.12. Alimta

5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region

5.13. Xtandi

5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region

5.14. Tarceva

5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region

5.15. Perjeta

5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region

5.16. Other drugs

5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region

Chapter: 6: CANCER THERAPEUTICS MARKET, BY REGION

6.1. Overview

6.1.1. Market size and forecast

6.2. North America

6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country

6.2.2.1. U.S.

6.2.2.1.1. U.S. market size and forecast, by application

6.2.2.2. Canada

6.2.2.2.1. Canada market size and forecast, by application

6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs

6.3. Europe

6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe Cancer Therapeutics market, by country

6.3.2.1. Germany

6.3.2.1.1. Germany market size and forecast, by application

6.3.2.2. France

6.3.2.2.1. France market size and forecast, by application

6.3.2.3. UK

6.3.2.3.1. UK market size and forecast, by application

6.3.2.4. Italy

6.3.2.4.1. Italy market size and forecast, by application

6.3.2.5. Spain

6.3.2.5.1. Spain market size and forecast, by application

6.3.2.6. Rest of Europe

6.3.2.6.1. Rest of Europe market size and forecast, by application

6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs

6.4. Asia-Pacific

6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country

6.4.2.1. Japan

6.4.2.1.1. Japan market size and forecast, by application

6.4.2.2. China

6.4.2.2.1. China market size and forecast, by application

6.4.2.3. India

6.4.2.3.1. India market size and forecast, by application

6.4.2.4. Rest of Asia-Pacific

6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by application

6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs

6.5. LAMEA

6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country

6.5.2.1. Latin America

6.5.2.1.1. Latin America market size and forecast, by application

6.5.2.2. Middle East

6.5.2.2.1. Middle-East market size and forecast, by application

6.5.2.3. Africa

6.5.2.3.1. Africa market size and forecast, by application

6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs

Chapter: 7: COMPANY PROFILES

7.1. AbbVie Inc.

7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Business performance
7.1.5. Key strategic moves and developments

7.2. Astellas Pharma Inc.

7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Business performance
7.2.5. Key strategic moves and developments

7.3. Bristol Myers Squibb Company

7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Business performance
7.3.5. Key strategic moves and developments

7.4. Celgene Corporation

7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Business performance

7.5. Eli Lilly and Company

7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Business performance
7.5.5. Key strategic moves and developments

7.6. F. Hoffmann-La Roche Ltd.

7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Business performance
7.6.5. Key strategic moves and developments

7.7. Johnson & Johnson

7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Business performance
7.7.5. Key strategic moves and developments

7.8. Merck & Co., Inc.

7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Business performance
7.8.5. Key strategic moves and developments

7.9. Novartis AG

7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Business performance
7.9.5. Key strategic moves and developments

7.10. Pfizer Inc.

7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Business performance
7.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 06. CANCER THERAPEUTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2016-2023 ($MILLION)
TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 08. CANCER THERAPEUTICS MARKET FOR OTHER CANCERS, BY REGION, 2016-2023 ($MILLION)
TABLE 09. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 10. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 11. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 12. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 13. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 14. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 15. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 16. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 17. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 18. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 19. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 20. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 21. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 22. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 23. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 24. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2016-2023 ($MILLION)
TABLE 25. CANCER THERAPEUTICS MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 26. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 27. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 28. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 31. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 32. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 34. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 35. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 36. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 39. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 41. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 42. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 43. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 44. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 46. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 47. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 48. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 49. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 50. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 51. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 52. LAMEA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2016-2023 ($MILLION)
TABLE 53. ABBVIE: COMPANY SNAPSHOT
TABLE 54. ABBVIE: OPERATING SEGMENTS
TABLE 55. ASTELLAS: COMPANY SNAPSHOT
TABLE 56. ASTELLAS: OPERATING SEGMENTS
TABLE 57. BMS: COMPANY SNAPSHOT
TABLE 58. BMS: OPERATING SEGMENTS
TABLE 59. CELGENE: COMPANY SNAPSHOT
TABLE 60. CELGENE: OPERATING SEGMENTS
TABLE 61. ELI LILLY: COMPANY SNAPSHOT
TABLE 62. ELI LILLY: OPERATING SEGMENTS
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENTS
TABLE 65. J&J: COMPANY SNAPSHOT
TABLE 66. J&J: OPERATING SEGMENTS
TABLE 67. MERCK: COMPANY SNAPSHOT
TABLE 68. MERCK: OPERATING SEGMENTS
TABLE 69. NOVARTIS: COMPANY SNAPSHOT
TABLE 70. NOVARTIS: OPERATING SEGMENTS
TABLE 71. PFIZER: COMPANY SNAPSHOT
TABLE 72. PFIZER: OPERATING SEGMENTS

LIST OF FIGURES

FIGURE 01. CANCER THERAPEUTICS MARKET: SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016-2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2018*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016-2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2016
FIGURE 07. BARGAINING POWER OF BUYERS: LOW
FIGURE 08. BARGAINING POWER OF SUPPLIERS: MODERATE
FIGURE 09. THREAT OF NEW ENTRANTS: MODERATE
FIGURE 10. THREAT OF SUBSTITUTION: HIGH
FIGURE 11. COMPETITIVE RIVALRY: HIGH
FIGURE 12. CANCER THERAPEUTICS MARKET: IMPACT ANALYSES
FIGURE 13. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (MEN)
FIGURE 14. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (WOMEN)
FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR BLOOD CANCER, 2016 AND 2023 ($MILLION)
FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR LUNG CANCER, 2016 AND 2023 ($MILLION)
FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR BREAST CANCER, 2016 AND 2023 ($MILLION)
FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR COLORECTAL CANCER, 2016 AND 2023 ($MILLION)
FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR PROSTATE CANCER, 2016 AND 2023 ($MILLION)
FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF CANCER THERAPEUTICS MARKET FOR PROSTATE CANCER, 2016 AND 2023 ($MILLION)
FIGURE 21. COMPARATIVE REGION ANALYSIS OF REVLIMID CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 22. COMPARATIVE REGION ANALYSIS OF AVASTIN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 23. COMPARATIVE REGION ANALYSIS OF HERCEPTIN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 24. COMPARATIVE REGION ANALYSIS OF RITUXAN CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 25. COMPARATIVE REGION ANALYSIS OF OPDIVO CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 26. COMPARATIVE REGION ANALYSIS OF GLEEVEC CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 27. COMPARATIVE REGION ANALYSIS OF VELCADE CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 28. COMPARATIVE REGION ANALYSIS OF IMBRUVICA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 29. COMPARATIVE REGION ANALYSIS OF IBRANCE CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 30. COMPARATIVE REGION ANALYSIS OF ZYTIGA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 31. COMPARATIVE REGION ANALYSIS OF ALIMTA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 32. COMPARATIVE REGION ANALYSIS OF XTANDI CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 33. COMPARATIVE REGION ANALYSIS OF TARCEVA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 34. COMPARATIVE REGION ANALYSIS OF PERJETA CANCER THERAPEUTICS MARKET, 2016 AND 2023 ($MILLION)
FIGURE 35. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, 2016 AND 2023 ($MILLION)
FIGURE 36. ABBVIE: NET SALES, 2015-2017 ($MILLION)
FIGURE 37. ABBVIE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 38. ABBVIE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 39. ASTELLAS: NET SALES, 2015-2017 ($MILLION)
FIGURE 40. ASTELLAS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 41. ASTELLAS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 42. BMS: NET SALES, 2015-2017 ($MILLION)
FIGURE 43. BMS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 44. BMS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 45. CELGENE: NET SALES, 2015-2017 ($MILLION)
FIGURE 46. CELGENE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 47. CELGENE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 48. ELI LILLY: NET SALES, 2015-2017 ($MILLION)
FIGURE 49. ELI LILLY: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 50. ELI LILLY: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 51. ROCHE: NET SALES, 2015-2017 ($MILLION)
FIGURE 52. ROCHE: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 53. ROCHE: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 54. J&J: NET SALES, 2015-2017 ($MILLION)
FIGURE 55. J&J: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 56. J&J: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 57. MERCK: NET SALES, 2015-2017 ($MILLION)
FIGURE 58. MERCK: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 59. MERCK: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 60. NOVARTIS: NET SALES, 2015-2017 ($MILLION)
FIGURE 61. NOVARTIS: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 62. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
FIGURE 63. PFIZER NET SALES, 2015-2017 ($MILLION)
FIGURE 64. PFIZER: REVENUE SHARE BY SEGMENT, 2017 (%)
FIGURE 65. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2017 (%)

 

The global cancer drugs market is experiencing a shift in therapeutic modalities i.e. from the traditional cytotoxic agents to newly develop targeted and immunotherapeutic modalities. The demand for targeted and biologics-based cancer therapeutics has increased considerably, owing to the increase in prevalence of cancer in both developed and developing economies.

The cancer therapeutic market growth is propelled by upsurge in growth of geriatric population, increase in collaboration between pharmaceutical companies for development of novel cancer therapeutics, and surge in cancer awareness among populace.

The use of cancer therapeutics is highest in North America, owing to availability of oncology drugs, increased cancer awareness, and heavy expenditure by the government on healthcare, which is followed by Europe and Asia-Pacific. In addition, pharmaceutical companies have focused on expanding their presence in the emerging economies, which is anticipated to drive the market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Cancer Therapeutics Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $3456
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $3840
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5370
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6450
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $8995
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo